TARS - Tarsus Pharmaceuticals Inc
IEX Last Trade
27.05
-0.550 -2.033%
Share volume: 636,703
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$27.60
-0.55
-1.99%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-11 | 2022-11-09 | 2023-03-17 | 2023-05-09 | 2023-08-10 | 2023-11-09 | 2024-02-27 | 2024-05-08 | |
| Assets | |||||||||
| Total Assets | 252.828 M | 236.465 M | 227.863 M | 211.214 M | 188.927 M | 268.332 M | 265.491 M | 349.278 M | |
| Current Assets | 250.283 M | 234.078 M | 225.375 M | 208.646 M | 183.476 M | 259.277 M | 256.131 M | 340.724 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 15.000 K | 3.107 M | 4.036 M | |
| Other Current Assets | 4.300 M | 3.494 M | 4.767 M | 4.509 M | 5.002 M | 6.007 M | 7.868 M | 6.803 M | |
| Short Term Investments | 4.300 M | 3.494 M | 4.767 M | 4.509 M | 5.002 M | 6.007 M | 7.868 M | 6.803 M | |
| Total Receivables | 620.000 K | 4.012 M | 3.582 M | 2.918 M | 246.000 K | 6.370 M | 17.714 M | 31.361 M | |
| Current Cash | 245.363 M | 226.572 M | 217.026 M | 201.219 M | 178.228 M | 246.885 M | 227.442 M | 298.524 M | |
| Total Non-current Assets | 2.545 M | 2.387 M | 2.488 M | 2.568 M | 5.451 M | 9.055 M | 9.360 M | 8.554 M | |
| Property Plant Equipment | 963.000 K | 951.000 K | 957.000 K | 1.193 M | 1.541 M | 1.614 M | 1.468 M | 1.338 M | |
| Other Assets | 1.413 M | 1.279 M | 1.160 M | 1.069 M | 3.588 M | 3.264 M | 3.394 M | 3.449 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 3.967 M | 3.867 M | 3.767 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 252.828 M | 236.465 M | 227.863 M | 211.214 M | 188.927 M | 268.332 M | 265.491 M | 349.278 M | |
| Total liabilities | 31.323 M | 33.838 M | 34.963 M | 37.810 M | 41.198 M | 54.668 M | 68.503 M | 74.067 M | |
| Total current liabilities | 11.718 M | 14.273 M | 15.429 M | 13.255 M | 14.765 M | 23.249 M | 36.936 M | 42.528 M | |
| Accounts Payable | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 343.000 K | 209.000 K | 100.000 K | 40.000 K | 1.826 M | 1.711 M | 1.748 M | 1.606 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 19.262 M | 19.356 M | 19.434 M | 24.515 M | 24.607 M | 29.708 M | 29.819 M | 29.933 M | |
| Other liabilities | 343.000 K | 209.000 K | 100.000 K | 40.000 K | 1.826 M | 1.711 M | 1.748 M | 1.606 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 221.505 M | 202.627 M | 192.900 M | 173.404 M | 147.729 M | 213.664 M | 196.988 M | 275.211 M | |
| Common stock | 24.333 M | 26.662 M | 26.774 M | 26.742 M | 26.816 M | 30.622 M | 33.353 M | 35.301 M | |
| Retained earnings | -72.653 M | -95.164 M | -108.763 M | -132.182 M | -163.606 M | -202.754 M | -244.656 M | -280.387 M |